Semin Liver Dis 1998; 18(4): 415-424
DOI: 10.1055/s-2007-1007174
ORIGINAL ARTICLE

© 1998 by Thieme Medical Publishers, Inc.

Glutathione Therapy: From Prodrugs to Genes

Mary E. Anderson, Jia-Li Luo
  • Department of Microbiology and Molecular Cell Sciences, University of Memphis, Memphis, Tennessee
Further Information

Publication History

Publication Date:
16 April 2008 (online)

ABSTRACT

Glutathione (GSH; L-γ-glutamyl-L-cysteineglycine) is found in almost all mammalian cells, and liver has very high intracellular levels of GSH. It has many cellular functions, such as being a coenzyme, maintaining thiol/disulfide status, protection against toxic compounds and oxidative stress. GSH levels have been reported to be low in a number of pathological conditions; thus methods for increasing GSH levels are desirable. GSH may be increased by supplying its amino acid precursor, cysteine, in the form of prodrugs, such as N-acetylcysteine (NAC) and 2-oxothiazolidine-4-carboxylate (OTC). It may also be increased by giving γ-glutamylcysteine, a dipeptide precursor. GSH monoester and GSH diester are effective GSH delivery drugs. Such compounds may be therapeutically useful. Gene therapy may be useful for longer term therapy of GSH deficiency.

    >